Evidence map›Paper›PMID 39807886›Full record

ArticleAntimicrobial agents and chemotherapy2025

Nonclinical and clinical characterization of the absorption, metabolism, and excretion of islatravir.

Kerry L Fillgrove, Randolph P Matthews, Bing Lu, Yuexia Liang, Munjal Patel, Wen Liu, Catherine Z Matthews, Yang Liu, S Aubrey Stoch, Rosa I Sanchez and 1 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kerry L Fillgrove *Merck & Co., Inc, Rahway, New Jersey, USA.
Randolph P Matthews *Merck & Co., Inc, Rahway, New Jersey, USA.ORCID 0000-0002-8403-267X
Bing LuMerck & Co., Inc, Rahway, New Jersey, USA.
Yuexia LiangMerck & Co., Inc, Rahway, New Jersey, USA.
Munjal PatelMerck & Co., Inc, Rahway, New Jersey, USA.ORCID 0000-0001-6892-0899
Wen LiuMerck & Co., Inc, Rahway, New Jersey, USA.
Catherine Z MatthewsMerck & Co., Inc, Rahway, New Jersey, USA.
Yang LiuMerck & Co., Inc, Rahway, New Jersey, USA.
S Aubrey StochMerck & Co., Inc, Rahway, New Jersey, USA.
Rosa I SanchezMerck & Co., Inc, Rahway, New Jersey, USA.
Marian IwamotoMerck & Co., Inc, Rahway, New Jersey, USA.

Funding

Merck (Merck & Co., Inc., Rahway, NJ, USA) N/A
6 · The paper itself

Abstract

The development of new and improved antiretroviral therapies that allow for alternative dosing schedules is needed for people living with HIV-1. Islatravir is a deoxyadenosine analog in development for the treatment of HIV-1 that suppresses HIV-1 replication via multiple mechanisms of action, including reverse transcriptase translocation inhibition and delayed chain termination. Islatravir is differentiated from other HIV-1 antiretrovirals by its high potency, long

Indexed as

Anti-HIV AgentsDeoxyadenosinesAdultAnimalsDogsFemaleHIV-1HIV InfectionsHumansMaleRatsRats, Sprague-DawleyAnti-HIV AgentsDeoxyadenosinesislatravirabsorptionexcretionhuman immunodeficiency virusmass balance, metabolite profilingmetabolismnucleoside reverse transcriptase translocation inhibitionpharmacokineticsphase 1

Identifiers

PMID39807886
PMCPMC11823625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.